NCT00779181

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Addrenex Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	ADX415	ADX415 taken three times a day to achieve a high total daily dose
DRUG	ADX415	ADX415 taken three times a day to achieve a mid level total daily dose
DRUG	ADX415	ADX415 taken three times a day to achieve a low total daily dose
DRUG	Placebo	Placebo taken three times a day

Timeline

• Start date: 2008-10-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2008-10-24
• Last updated: 2008-12-17

Locations

3 sites across 1 country: United States